Proteomics International Laboratories Limited (PIQ.AX)
AUD 0.64
(-2.31%)
AUD 0.64
(-2.31%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 | -1.12 Million AUD | -358.29% |
| 2023 | -1.61 Million AUD | -184.04% |
| 2022 | -568.61 Thousand AUD | -214.39% |
| 2021 | 497.08 Thousand AUD | -14.98% |
| 2020 | 584.64 Thousand AUD | -57.64% |
| 2019 | 1.38 Million AUD | 203.75% |
| 2018 | -1.33 Million AUD | 1.8% |
| 2017 | -1.35 Million AUD | -25.45% |
| 2016 | -1.07 Million AUD | -482.67% |
| 2015 | 282.16 Thousand AUD | -61.52% |
| 2014 | 733.37 Thousand AUD | -41.59% |
| 2013 | 1.25 Million AUD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q4 | 1.55 Million AUD | 0.0% |
| 2024 Q2 | -3.14 Million AUD | 0.0% |
| 2024 FY | -7.4 Million AUD | -358.29% |
| 2023 Q1 | -187.24 Thousand AUD | 93.56% |
| 2023 Q2 | -3.51 Million AUD | -1779.08% |
| 2023 FY | -1.61 Million AUD | -184.04% |
| 2023 Q3 | 605.03 Thousand AUD | 117.2% |
| 2023 Q4 | -3.73 Million AUD | -717.37% |
| 2022 Q2 | -2.25 Million AUD | 0.0% |
| 2022 Q4 | -2.9 Million AUD | -489.47% |
| 2022 FY | -568.61 Thousand AUD | -214.39% |
| 2022 Q3 | 746.27 Thousand AUD | 133.05% |
| 2021 FY | 497.08 Thousand AUD | -14.98% |
| 2021 Q1 | 355.76 Thousand AUD | 128.16% |
| 2021 Q2 | -1.2 Million AUD | -437.33% |
| 2021 Q3 | 707.24 Thousand AUD | 158.93% |
| 2021 Q4 | -1.4 Million AUD | -298.24% |
| 2020 FY | 584.64 Thousand AUD | -57.64% |
| 2020 Q4 | -1.26 Million AUD | -455.14% |
| 2020 Q3 | 355.76 Thousand AUD | 155.36% |
| 2020 Q2 | -642.63 Thousand AUD | 0.0% |
| 2019 Q1 | 401.24 Thousand AUD | -69.29% |
| 2019 Q4 | -991.5 Thousand AUD | -370.15% |
| 2019 Q3 | 367.01 Thousand AUD | -54.27% |
| 2019 Q2 | 802.49 Thousand AUD | 100.0% |
| 2019 FY | 1.38 Million AUD | 203.75% |
| 2018 Q2 | 142.68 Thousand AUD | 100.0% |
| 2018 Q1 | 71.34 Thousand AUD | -93.05% |
| 2018 Q4 | 1.3 Million AUD | 344.21% |
| 2018 Q3 | 294.11 Thousand AUD | 106.13% |
| 2018 FY | -1.33 Million AUD | 1.8% |
| 2017 Q3 | 231.33 Thousand AUD | -3.19% |
| 2017 Q2 | 238.96 Thousand AUD | 100.0% |
| 2017 Q4 | 1.02 Million AUD | 343.63% |
| 2017 FY | -1.35 Million AUD | -25.45% |
| 2017 Q1 | 119.48 Thousand AUD | -86.43% |
| 2016 Q2 | 120.62 Thousand AUD | -20.69% |
| 2016 FY | -1.07 Million AUD | -482.67% |
| 2016 Q3 | 204.21 Thousand AUD | 69.29% |
| 2016 Q1 | 152.09 Thousand AUD | -67.22% |
| 2016 Q4 | 880.56 Thousand AUD | 331.2% |
| 2015 FY | 282.16 Thousand AUD | -61.52% |
| 2015 Q1 | - AUD | 0.0% |
| 2015 Q3 | 152.09 Thousand AUD | -13.71% |
| 2015 Q4 | 463.95 Thousand AUD | 205.04% |
| 2015 Q2 | 176.25 Thousand AUD | 0.0% |
| 2014 Q2 | - AUD | 0.0% |
| 2014 Q3 | - AUD | 0.0% |
| 2014 Q4 | - AUD | 0.0% |
| 2014 FY | 733.37 Thousand AUD | -41.59% |
| 2013 FY | 1.25 Million AUD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| EZZ Life Science Holdings Limited | 50.94 Million AUD | 102.205% |
| Anatara Lifesciences Ltd | -748.91 Thousand AUD | -49.976% |
| Zelira Therapeutics Limited | 10.28 Thousand AUD | 11021.713% |
| Biome Australia Limited | 7.66 Million AUD | 114.645% |
| Patrys Limited | 1.39 Million AUD | 180.564% |
| Orthocell Limited | 3.68 Million AUD | 130.452% |
| Imugene Limited | -5.83 Million AUD | 80.767% |
| Noxopharm Limited | -534.81 Thousand AUD | -110.016% |
| PYC Therapeutics Limited | 22.05 Million AUD | 105.092% |
| Chimeric Therapeutics Limited | 7.45 Million AUD | 115.069% |
| Prescient Therapeutics Limited | 3.71 Million AUD | 130.255% |
| Cynata Therapeutics Limited | 2.31 Million AUD | 148.504% |
| CSL Limited | 15.28 Billion AUD | 100.007% |
| Arovella Therapeutics Limited | -25.97 Thousand AUD | -4223.45% |
| Bio-Gene Technology Limited | -301.44 Thousand AUD | -272.597% |
| Clinuvel Pharmaceuticals Limited | 78.09 Million AUD | 101.438% |
| Starpharma Holdings Limited | 7.65 Million AUD | 114.669% |
| Nanollose Limited | -348.95 Thousand AUD | -221.875% |
| Memphasys Limited | 1606.00 AUD | 70037.049% |
| Invex Therapeutics Ltd | 1.21 Million AUD | 192.653% |
| NeuroScientific Biopharmaceuticals Limited | -91.33 Thousand AUD | -1129.72% |
| Amplia Therapeutics Limited | 4.01 Million AUD | 128.004% |
| Botanix Pharmaceuticals Limited | -6.55 Million AUD | 82.856% |
| Island Pharmaceuticals Limited | 1.25 Million AUD | 189.742% |
| Race Oncology Limited | 1.38 Million AUD | 180.81% |
| Nyrada Inc. | -5164.07 AUD | -21650.073% |
| Telix Pharmaceuticals Limited | 308.5 Million AUD | 100.364% |
| Dimerix Limited | 583.47 Thousand AUD | 292.499% |
| PharmAust Limited | -1641.00 AUD | -68345.399% |
| Immutep Limited | 1.44 Million AUD | 177.788% |
| Clarity Pharmaceuticals Ltd | 11.5 Million AUD | 109.761% |
| Alterity Therapeutics Limited | 3.8 Million AUD | 129.519% |
| BTC Health Limited | 16.36 Thousand AUD | 6965.458% |
| Acrux Limited | -1.28 Million AUD | 12.524% |
| Neuren Pharmaceuticals Limited | 205.17 Million AUD | 100.547% |
| Biotron Limited | -40.49 Thousand AUD | -2673.443% |
| Tissue Repair Ltd | 150.51 Thousand AUD | 846.25% |
| AdAlta Limited | 1.5 Million AUD | 174.486% |
| Radiopharm Theranostics Limited | -21.3 Million AUD | 94.729% |
| Hexima Limited | - AUD | Infinity% |
| AnteoTech Limited | 460.39 Thousand AUD | 343.961% |
| Paradigm Biopharmaceuticals Limited | 56.81 Thousand AUD | 2077.028% |
| Recce Pharmaceuticals Ltd | -366.76 Thousand AUD | -206.24% |
| Avecho Biotechnology Limited | -43.79 Thousand AUD | -2464.651% |
| Actinogen Medical Limited | 9.93 Million AUD | 111.309% |
| Immuron Limited | 3.33 Million AUD | 133.661% |
| Argenica Therapeutics Limited | 2.59 Million AUD | 143.234% |